CD8A and melanoma: The vaccine which could be administered orally or intranasally, would likely to induce an antigen specific immune response against glioma and melanoma cells, triggering immune effectors including antigen specific CD8+ cells and antibodies as has been detected in other studies utilizing LAB as antigen carriers.